#USA #Bradenton #Drug Delivery #continuity #PinPrint

Continuity Biosciences Expands Horizons with PinPrint Investment

In a move that promises to redefine drug delivery systems in the aesthetic and cosmetic markets, Continuity Biosciences, LLC recently announced a strategic investment in PinPrint, Inc. This collaboration is set to leverage cutting-edge 3D printing technology, notably in the realm of microarray patches that offer innovative solutions for drug administration, particularly for vaccinations and active agents via the skin.

The technology behind PinPrint was developed by the renowned Dr. Joseph DeSimone, a distinguished chemist and inventor who is also the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University. Dr. DeSimone's team has created a revolutionary platform that significantly improves precision in constructing microchannels and cavities, which are essential for biomedical applications like micro-needle patches and microfluidic devices.

Dr. DeSimone expressed the importance of this technology: “By integrating high-resolution 3D printing with advanced drug administration methods, we aim to redefine the patient experience across therapeutic and aesthetic categories, setting a new standard for precision, personalization, and comfort.”

The investment aligns perfectly with Continuity's mission to push the boundaries of selective delivery technologies. The company has been engaged in developing nanofluidic platforms through its collaboration with the Grattoni Lab at the Houston Methodist Hospital, focusing on zero-order release capabilities for implanted systems. Dr. Ramakrishna Venugopalan, Co-Founder and CEO of Continuity Biosciences, stated, “This strategic investment allows us to transition from implanted nanofluidic systems to a non-implanted microfluidic platform, paving the way for more efficient administration of dermatological, aesthetic, and cosmetic agents directly into the dermis.”

As part of the investment agreement, Dr. Venugopalan will join the Board of Directors at PinPrint, marking a significant step in the cross-pollination of expertise between the two organizations. Renee Ryan, Co-Founder and CEO of PinPrint, welcomed Dr. Venugopalan to the board, emphasizing his extensive knowledge and strategic vision in the sector, which will be paramount as they continue to innovate in drug and vaccine delivery.

Continuity Biosciences, headquartered in Bradenton, Florida, is dedicated to developing advanced drug delivery technologies aimed at chronic and complex diseases. With operations extending into Houston, Texas, the company is committed to enhancing the accuracy and efficacy of therapeutic administration. To learn more about Continuity and its innovative work, visit continuitybiosciences.com.

On the other hand, PinPrint, Inc. is at the forefront of transforming drug and vaccine administration through precision micro-needle platforms that are 3D printed. By revolutionizing how medications are delivered, PinPrint aspires to improve patient outcomes and comfort across various therapeutic and aesthetic applications.

With this partnership, both companies are set to make significant strides in the field of drug delivery, potentially reshaping the landscape of cosmetic and aesthetic medicine for the better.